The document “Remuneration Update and Employee Equity Incentives” was lodged with ASX on 16 December 2021. Please click to review the full announcement at ASX.
Imagion Biosystems is pleased to advise that it has now received the full $4.8 million from the exercise of all 96,706,395 listed options (IBXO) which
The following Appendix 2A was announced via ASX on 1 Dec 2021. Please click to review full announcement.
The following cleansing notice was lodged with ASX on December 1, 2021: Imagion Biosystems Limited (ASX: IBX) (the Company) gives notice that, between 26 November
The following Appendix 2A was announced via ASX on 25 Nov 2021. Please click to review full announcement.
The following cleansing notice was lodged with ASX on November 25, 2021: Imagion Biosystems Limited (ASX: IBX) (the Company) gives notice that, between 19 November
The document “Appendix 3Y Change of Director’s Interest Notice” was lodged with ASX on 22 November, 2021. Please click to review the full announcement at
The document “Application for quotation of +securities” was lodged with ASX on November 18, 2021. Please click to review the full announcement at ASX.
The following cleansing notice was lodged with ASX on 18 November 2021: Imagion Biosystems Limited (ASX: IBX) (the Company) gives notice that, between 12 November
Imagion Biosystems Limited (ASX: IBX) (the Company) gives notice that, between 29 October 2021 and 4 November 2021 the Company issued 7,075,649 fully paid ordinary
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance